V212 is the firm’s investigational inactivated VZV vaccine to prevent herpes zoster (HZ) and HZ-related complications in immunocompromised subjects with the age of 18 years and above. The
Sapacitabine (CYC682), an orally-available nucleoside analogue, acts via a novel DNA single-strand breaking mechanism, resulting in production of DNA double strand breaks (DSBs) and/or checkpoint activation. Primary endpoint of
The study showed that patients with well-controlled asthma have been able to change to the once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI) 100/25, an inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA)
The phase 3 ADAPT clinical trial, which is assessing rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of metastatic renal cell carcinoma (mRCC), has been concluded as futility
Currently, Inotuzumab ozogamicin is being assessed for treatment of adult patients with acute lymphoblastic leukemia (ALL) both in relapsed and refractory B-cell precursor forms. The drug will now
Alecensa, which is an oral medicine produced at Chugai Kamakura, is being developed for people with NSCLC whose tumours are identified as ALK-positive. The European Commission has granted approval
The phase II INFORAAA clinical trial will target the second indication for Traumakine. Traumakine is based on a patent-protected use of interferon beta to prevent leakage of vascular beds
Tivantinib is an investigational oral inhibitor of the MET receptor tyrosine kinase, which is currently under phase 3 clinical development for the second-line treatment of hepatocellular carcinoma (HCC),
The study, dubbed Olympiad, was carried out in HER2-negative metastatic breast cancer patients having germline BRCA1 or BRCA2 mutations with the drug candidate trialed against physician’s choice of a
The firm has announced top-line results from ORAL Strategy, a Phase 3B/4 study of Xeljanz (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.